Wall Street Zen Downgrades Medpace (NASDAQ:MEDP) to Hold

by · The Markets Daily

Medpace (NASDAQ:MEDP – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

A number of other equities analysts have also weighed in on MEDP. Cowen reaffirmed a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Rothschild & Co Redburn lowered shares of Medpace from a “buy” rating to a “neutral” rating and increased their price objective for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Barclays boosted their target price on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Mizuho raised their target price on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. Finally, BMO Capital Markets assumed coverage on shares of Medpace in a research note on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $490.82.

Read Our Latest Stock Analysis on MEDP

Medpace Trading Up 1.5%

NASDAQ MEDP opened at $568.36 on Friday. Medpace has a 12 month low of $250.05 and a 12 month high of $626.26. The stock has a market cap of $16.01 billion, a price-to-earnings ratio of 39.75, a PEG ratio of 2.14 and a beta of 1.43. The company’s 50 day moving average is $574.72 and its two-hundred day moving average is $473.10.

Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same period in the prior year, the company posted $3.01 earnings per share. The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Sell-side analysts forecast that Medpace will post 12.29 EPS for the current year.

Insider Activity at Medpace

In other news, CEO August J. Troendle sold 59,025 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This trade represents a 7.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Jesse J. Geiger sold 21,503 shares of Medpace stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total value of $12,808,476.98. Following the completion of the transaction, the president owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This trade represents a 58.91% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 387,925 shares of company stock valued at $233,386,647. Insiders own 20.30% of the company’s stock.

Institutional Trading of Medpace

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC grew its stake in shares of Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares during the last quarter. Norges Bank bought a new stake in shares of Medpace during the 2nd quarter worth approximately $66,597,000. Arrowstreet Capital Limited Partnership boosted its holdings in Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after acquiring an additional 211,411 shares during the period. Clarkston Capital Partners LLC bought a new position in Medpace in the 2nd quarter valued at $40,569,000. Finally, Mawer Investment Management Ltd. grew its position in Medpace by 17.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after acquiring an additional 121,213 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

(Get Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Featured Stories